Delving into the Latest Updates on CHOLINE C-11 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

11C-choline, 11C-choline chloride

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic Cancer

Inactive Indication-

Originator Organization

MAYO CLINIC PET RADIOCHEMISTRY FACILITY

Active Organization

MAYO CLINIC PET RADIOCHEMISTRY FACILITY

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 Sep 2012),

Prostatic Cancer

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC5H14ClNO

InChIKeySGMZJAMFUVOLNK-ULWFUOSBSA-M

CAS Registry87591-54-6

It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection. The purpose of this study is the ability of 11C-Choline PET/CT to evaluate the baseline condition of LAM patients and the efficacy of rapamycin after treatment.

Start Date01 Nov 2021

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT04693169

/ Active, not recruitingNot ApplicableIIT

[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

Start Date15 Jan 2021

Sponsor / Collaborator

Beijing Cancer Hospital

NCT04560725

/ Active, not recruitingNot ApplicableIIT

PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).

Start Date22 Oct 2020

Sponsor / Collaborator-

100 Clinical Results associated with CHOLINE C-11

Login to view more data

100 Translational Medicine associated with CHOLINE C-11

Login to view more data

100 Patents (Medical) associated with CHOLINE C-11

Login to view more data

9

Literatures (Medical) associated with CHOLINE C-11

01 Aug 2020·Journal of UrologyQ1 · MEDICINE

Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸ Ga-PSMA and ¹¹ C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections

Q1 · MEDICINE

Article

Author: Gill, Inderbir S. ; Joniau, Steven ; Fossati, Nicola ; Buchner, Alexander ; Mottrie, Alexander ; Boeri, Luca ; Battaglia, Antonino ; Hiester, Andreas ; Tilki, Derya ; Montorsi, Francesco ; Juenemann, Klaus-Peter ; Karnes, R. Jeffrey ; Suardi, Nazareno ; Van Poppel, Hendrik ; Nini, Alessandro ; Heidenreich, Axel ; Pfister, David ; Graefen, Markus ; Stief, Christian ; Osmonov, Daniar ; Kretschmer, Alexander ; Shariat, Shahrokh ; Scarcella, Simone ; Galosi, Andrea Benedetto ; Briganti, Alberto ; Albers, Peter ; Robesti, Daniele ; Gandaglia, Giorgio

PURPOSEWe compared the use of ¹¹C-choline and ⁶⁸Ga-prostate specific membrane antigen in men undergoing salvage lymph node dissection for nodal recurrent prostate cancer.MATERIALS AND METHODSThe study included 641 patients who experienced prostate specific antigen rise and nodal recurrence after radical prostatectomy and underwent salvage lymph node dissection. Lymph node recurrence was documented by positron emission tomography/computerized tomography using ¹¹C-choline (407, 63%) or ⁶⁸Ga-PSMA ligand (234, 37%). The outcome was underestimation of tumor burden (difference between number of positive nodes on final pathology and number of positive spots at positron emission tomography/computerized tomography). Multivariable analysis tested the association between positron emission tomography/computerized tomography tracer (¹¹C-choline vs ⁶⁸Ga-PSMA) and tumor burden underestimation.RESULTSOverall the extent of tumor burden underestimation was significantly higher in the ¹¹C-choline group compared to the ⁶⁸Ga-PSMA group (p <0.0001), which was confirmed on multivariable analysis (p=0.028). Repeating these analyses according to prostate specific antigen, tumor burden underestimation was lower with ⁶⁸Ga-PSMA only when prostate specific antigen was 1.5 ng/ml or less. Conversely, the underestimation of the 2 tracers became similar when prostate specific antigen was greater than 1.5 ng/ml. Furthermore, we evaluated the risk of underestimation by number of positive spots on positron emission tomography/computerized tomography. The higher the number of positive spots the higher the underestimation of tumor burden regardless of the tracer used (p=0.2).CONCLUSIONSPositron emission tomography/computerized tomography significantly underestimates the burden of prostate cancer recurrence, regardless of the tracer used. ⁶⁸Ga-PSMA was associated with a lower rate of underestimation in patients with a prostate specific antigen below 1.5 ng/ml and a limited nodal tumor load. In all other men there was no benefit from ⁶⁸Ga-PSMA over ¹¹C-choline in assessing the extent of nodal recurrence.

01 Dec 2019·EJNMMI Research

Optimization of parathyroid 11C-choline PET protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism

Article

Author: Telenga, Eef D ; Noordzij, Walter ; Hubalewska-Dydejczyk, Alicja ; El Moumni, Mostafa ; Boellaard, Ronald ; Brouwers, Adrienne H ; Opalińska, Marta ; Luurtsema, Gert ; Kruijff, Schelto ; Noltes, Milou E ; Vállez García, David ; Trofimiuk-Müldner, Malgorzata ; Dierckx, Rudi A J O

PURPOSETo evaluate the optimal tracer uptake time, the minimal amount of radioactivity and the inter-observer agreement for ¹¹C-choline positron emission tomography/computed tomography (PET/CT) in patients with primary hyperparathyroidism (pHPT).METHODSTwenty-one patients with biochemically proven pHPT were retrospectively studied after injection of 6.3 ± 1.2 MBq/kg ¹¹C-choline. PET data of the first nine patients, scanned for up to 60 min, were reconstructed in 10-min frames from 10- to 60-min postinjection (p.i.), mimicking varying ¹¹C-choline uptake times. Parathyroid adenoma to background contrast ratios were calculated and compared, using standardized uptake values (SUVs). Data was reconstructed with varying scan durations (1, 2.5, 5, and 10 min) at 20-30-min p.i. (established optimal uptake time), mimicking less administered radioactivity. To establish the minimal required radioactivity, the SUVs in the shorter scan durations (1, 2.5, and 5 min) were compared to the 10-min scan duration to determine whether increased variability and/or statistical differences were observed. Four observers analyzed the ¹¹C-choline PET/CT in four randomized rounds for all patients.RESULTSSUVpeak of the adenoma decreased from 30 to 40 p.i. onwards. All adenoma/background contrast ratios did not differ from 20- to 30-min p.i. onwards. The SUVs of adenoma in the scan duration of 1, 2.5, and 5 min all differed significantly from the same SUV in the 10-min scan duration (all p = 0.012). However, the difference in absolute SUV adenoma values was well below 10% and therefore not considered clinically significant. The inter-observer analysis showed that the Fleiss' kappa of the 1-min scan were classified as "moderate," while these values were classified as "good" in the 2.5-, 5-, and 10-min scan duration. Observers scored lower certainty scores in the 1- and 2.5-min scans compared to the 5- and 10-min scan durations.CONCLUSIONThe optimal time to start PET/CT scanning in patients with pHPT is 20 min after mean injection of 6.3 MBq/kg ¹¹C-choline, with a recommended scan duration of at least 5 min. Alternatively, the radioactivity dose can be lowered by 50% while keeping a 10-min scan duration without losing the accuracy of ¹¹C-choline PET/CT interpretation.

01 Sep 2013·Clinical Nuclear MedicineQ3 · MEDICINE

The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL

Q3 · MEDICINE

Article

Author: Ceci, Francesco ; Costa, Stefano ; Fanti, Stefano ; Fuccio, Chiara ; Brunocilla, Eugenio ; Castellucci, Paolo ; Nanni, Cristina ; Mamede, Marcelo ; Schiavina, Riccardo ; Colletti, Patrick M ; Fantini, Lorenzo ; Ferretti, Alice ; Rubello, Domenico

PURPOSEThis study aims to evaluate the role of (11)C-choline PET/CT in patients with biochemical relapse after radical prostatectomy (RP) showing prostate-specific antigen (PSA) values lower than 0.5 ng/mL.METHODSWe performed (11)C-choline PET/CT in 71 consecutive patients previously treated with RP showing PSA values lower than 0.5 ng/mL. (11)C-Choline PET/CT was performed following standard procedure. (11)C-Choline PET/CT-positive findings were validated by transrectal ultrasonography + biopsy, repeated (11)C-choline PET/CT, other conventional imaging modality, and histology.RESULTS(11)C-Choline PET/CT was true positive in 15/71 (21.1%). (11)C-Choline uptake was observed in pelvic lymph nodes (7/71; 9.9%), in the prostatic bed (7/71; 9.9%), and in bone (1/71; 1.4%). Mean PSA, PSA doubling time (PSAdt), and PSA velocity (PSAvel) values ± SD in (11)C-choline PET/CT-positive patients was 0.37 ± 0.1 ng/mL, 3.4 ± 2.1 months, and 0.05 ± 0.1 ng/mL/yr, respectively. (11)C-Choline PET/CT was false negative in 2 patients and false positive in 1 patient. Among all variables, only PSAdt and the ongoing hormonal treatment were statistically significant in the prediction of a positive (11)C-choline PET/CT at multivariate analysis.CONCLUSIONS(11)C-Choline PET/CT could be used early after biochemical failure even if PSA values are very low, preferentially in hormonal resistant patients showing fast PSA kinetics. An early detection of the site of relapse could lead to a personalized and tailored treatment.

100 Deals associated with CHOLINE C-11

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10498	CHOLINE C-11	V09	DB09277

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	United States	MAYO CLINIC PET RADIOCHEMISTRY FACILITY	12 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	Transitional Cell Carcinoma	-	11C-Choline (2-min <sup>11</sup>C-CHO TB PET/CT scan)	xaldtqsojz(lwliejfjms) = There were no statistically significant differences in the distant organ metastasis by dual-phase imaging riaefdrldc (oqqbglbaqm ) View more	-	09 Jun 2024
				11C-Choline (1-h <sup>11</sup>C-CHO TB PET/CT scan)
EANM2021	Not Applicable	Prostatic Cancer Adjuvant serum PSA	103	[11C]Choline (Radical Prostatectomy (RP))	okufjohllk(luuhqqexdz) = cfsmipbrnw kyojevmhjy (biauixglrc ) View more	Positive	24 Sep 2021
				Other forms of treatment (radiotherapy, chemotherapy, hormonotherapy)	(yuoqnlroxz) = twyswrixyx iyxkptpamt (ywjvtqxxsz )
EANM2020	Not Applicable	Parathyroid Diseases	60	11C-Choline (Dual Isotope SPECT/CT)	(djkwykskvw) = bfwcrosbci yehhqvbwsv (rmxtwuigms, 90% - 100%)	-	18 Sep 2020
NCT02260817 (CTgov)	Phase 3	Recurrent Prostate Carcinoma \| Metastatic Prostate Carcinoma	109	11C-choline (11C-choline for Staging of Recurrent Prostate Cancer)	peepvcnyup(negdxobitk) = devnfnmwmt rstxmibqcv (naefzbxwvc, ymisiybczk - lnkxahloyd) View more	-	17 Dec 2019
				11C-choline (11C-choline Comparison Study of CT and MR Modalities)	peepvcnyup(negdxobitk) = hqobvcurho rstxmibqcv (naefzbxwvc, kccvapsxgp - ftoqtikkom) View more
SNMMI2019	Not Applicable	-	-	11C-CHOLINE18F-FDGLINE (18F-FDG PET/CT)	idmuyumnlk(ycvigaybzc) = yaxhghkzfv djycpmeygn (mstdwonhyy ) View more	-	21 May 2019
EANM2018	Not Applicable	Prostatic Cancer	-	11C-Choline (PET/MR C11-Choline WB scan)	jzsnboomgp(ozxqdxqyxp) = zjcdtjlvtq ptyhcjayja (hpzjvksdgl, 11.78) View more	Positive	18 Sep 2018
				11C-Choline (mp-MR study)	jzsnboomgp(ozxqdxqyxp) = pwhoeecnsu ptyhcjayja (hpzjvksdgl, 11.78) View more
EANM2018	Not Applicable	Recurrent Prostate Carcinoma PSA	112	11C-Choline (Radical Prostatectomy (RP))	(qhvwbdnadi) = qtdhbkbqcs shovamaqth (catdyvzfsm ) View more	-	18 Sep 2018
				External Beam Radiotherapy (EBRT)	uiqewtkhlo(wmjwefanoa) = jaefgqmxxb izazpzcjzy (hvomumczhe )
SNMMI2018	Not Applicable	-	-	11 C-choline (11C-choline PET/CT)	(akbdobbtci) = lnvsnjszxk xjvcmombys (vhjvzwkhkx, 0.22 - 0.99) View more	-	23 May 2018
11C-Choline (EANM2017)	Not Applicable	Prostatic Cancer	5	11C-Choline (C11-Choline)	uuqtpcqckr(paizkyebfm) = wjhlpupeiv omckvvdebr (vyfrochbiy, 13.25)	Positive	11 Sep 2017
				11C-Choline (Multiparametric MR)	uuqtpcqckr(paizkyebfm) = qkdwenpbbl omckvvdebr (vyfrochbiy, 0.83)
MP77-01 (AUA2017)	Not Applicable	Prostatic Cancer PSA	266	11C-choline	rwdkmvhqsq(kngsaomyhc) = dueflelddo geuzgvypfp (grirgznxvn ) View more	-	01 Apr 2017
				11C-CHOLINE (68Ga-PSMA ligand)	rwdkmvhqsq(kngsaomyhc) = dyezaklkok geuzgvypfp (grirgznxvn ) View more